Clinical trials: Complete Response
Pathological Complete Response, Rectal Cancer
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
This study is designed as a single-center, phase II exploratory clinical trial to evaluate the pathological response rate and safety of sintilimab (PD-1 inhibitor) combined with XELOX regimen (oxaliplatin + capecitabine) for…
- Conditions
- Pathological Complete Response, Rectal Cancer, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07127497
- Testing
- Sintilimab combined with XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Hematologic Diseases, Chronic Myeloid Leukemia
Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach
Chronic myeloid leukemia (CML) is a model of targeted therapy for human malignancies. Over the past decade, a broad array of drugs designed to selectively inhibit protein tyrosine kinases (PTK) [i.e., tyrosine kinase inhibitors…
- Trial name
- ECOSTIM (NCT03540654)
- Testing
- Budget impact
- Where
- France
- Volunteers
- 355 people
- Sponsor
- University Hospital, Bordeaux
Rectal Cancer, Locally Advanced Rectal Cancer
Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer
The current trial is evaluating the impact of deep regional hyperthermia on the pathological complete response rate in locally advanced rectal cancer in the context of preoperative 5FU based radiochemotherapy.
- Conditions
- Rectal Cancer, Locally Advanced Rectal Cancer, Hyperthermia, Hyperthermic Radiochemotherapy
- Trial name
- HT01 (NCT02353858)
- Testing
- Deep regional hyperthermia, Radiotherapy, Chemotherapy (5-Fluorouracil)
- Where
- Germany
- Volunteers
- 78 people
- Sponsor
- University Hospital Tuebingen
Solid Tumor
Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Population and in Cancer Free Population.
Performance evaluation of diagnostic accuracy (Sensitivity and Specificity) of PanTum detect Test for detection of solid tumours in known cancer population (Sick population) and in cancer free (Healthy) population.
- Trial name
- NCT06456216
- Where
- India
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Max Healthcare Insititute Limited
Basal Cell Carcinoma
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulate more photosensitiser than normal cells.
- Trial name
- NCT00473343
- Testing
- Metvix® cream
- Where
- 7 sites in Australia
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Breast Neoplasms
Study of Tumor RNA Disruption Assay™ (RDA)
The purpose of this study is to find out if the pathological complete response (pCR) to chemotherapy given before surgery (neoadjuvant chemotherapy) could be predicted by the evaluation of the RNA (ribonucleic acids) disruption…
- Trial name
- RnaDx (NCT02239315)
- Testing
- Tumor RNA Disruption Assay™ (RDA)
- Where
- 4 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University of Toronto
Rectal Neoplasms, Rectal Cancer, Adenocarcinoma
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
The goal of this randomized controlled clinical trial is to learn if adding fruquintinib to short-course radiotherapy, tislelizumab, and CAPOX can improve neoadjuvant treatment response and is safe for adults with locally…
- Trial name
- TRIP-FAST (NCT07888309)
- Testing
- Short-Course Radiotherapy, Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Meningococcal Infection
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of…
- Trial name
- NCT01543087
- Testing
- blood sampling, bivalent rLP2086
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 698 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gastric Cancer (GC), Locally Advanced Gastric Cancer
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy.
- Trial name
- NCT07401199
- Testing
- Standard of Care PD-1 Inhibitors, Multimodal AI Assessment
- Where
- 9 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Qun Zhao
Lymphoma, B-Cell
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy.
- Trial name
- NCT03681938
- Testing
- Autograft
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
To de-escalate radiation therapy in women with breast cancer.
- Trial name
- ROSALIE (NCT05866458)
- Where
- 27 sites in Australia, Canada
- Volunteers
- 352 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients
In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve…
- Trial name
- ABLATIVE-2 (NCT05350722)
- Testing
- Single dose ablative radiotherapy
- Where
- 7 sites in Australia, Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Cancer, HER2-positive Breast Cancer
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
This phase II study evaluates the efficacy and safety of a de-escalated neoadjuvant chemotherapy regimen in patients with early-stage HER2-positive breast cancer.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer
- Trial name
- Opti-HER2 (NCT07421141)
- Testing
- Paclitaxel, trastuzumab, Pertuzumab
- Where
- Russia
- Volunteers
- 186 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
HER2-positive Breast Cancer, Early Breast Cancer (EBC)
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage…
- Trial name
- NCT07856303
- Testing
- SHR-A1811, Trastuzumab, Pertuzumab
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Fudan University
Breast Cancer, Triple Negative Breast Neoplasms
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer.
- Trial name
- NCT04335669
- Testing
- epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
- Where
- 24 sites in Denmark, Sweden
- Volunteers
- 325 people
- Sponsor
- Lund University Hospital
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is reported to be able to improve the outcomes for elderly acute myeloid leukemia (AML) in complete remission (CR).
- Conditions
- Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Elderly
- Trial name
- NCT03530085
- Testing
- Decitabine, Busulfan (BU), Fludarabine(Flu)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University